Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife appointments

This article was originally published in The Tan Sheet

Executive Summary

COO Gregory Probert will take on dual responsibilities of chief operating officer and president, the company announces August 2. Probert does not replace anyone as president as the position has recently been created, the Los Angeles-based firm reports. Probert, who joined Herbalife in August 2003, is responsible for the company's 60 markets located around the world. Steve Henig, PhD, will fill another new position as chief scientific officer, the company stated in a separate same-day release. Henig will be responsible for Herbalife's product R&D. The firm reported a successful first quarter with earnings increasing 83.3% from the prior year period to $27.5 mil. (1"The Tan Sheet" May 16, 2005, p. 18)...

You may also be interested in...



Herbalife China Expansion Slow But On Track For 2006, COO Predicts

Herbalife remains on track to build its presence in China despite delayed implementation of direct-selling regulations in that country

Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Falling Sales Force New Priorities At Roche

The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel